LONDON--(BUSINESS WIRE)--Technavio has announced their latest pipeline analysis report on the diabetic neuropathy market. The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat diabetic neuropathy.
This report by Technavio presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market in the future.
This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing
Diabetic neuropathy: Market overview
Diabetic neuropathy is a type of nerve damage caused by diabetes. Over time, hyperglycemia and high levels of fats can damage nerves. Neuropathy can be caused by both type 1 and type 2 diabetes. Furthermore, diabetic neuropathy is classified into peripheral neuropathy, proximal neuropathy, autonomic neuropathy, and focal neuropathy. The pathogenesis of diabetic neuropathy is complex and is marked by both metabolic and vascular factors including hyperglycemia, toxic adiposity, oxidative stress, mitochondrial dysfunction, activation of the polyol pathway, accumulation of advanced glycation end products, and elevation of inflammatory markers.
According to a senior market research analyst at Technavio, “According to the Centers for Disease Control and Prevention, around 60-70% of people with diabetes have diabetic neuropathy. The highest number of neuropathic problems are among the people who have had diabetes for at least 25 years. Also, diabetic nerve problems are more common in people who have problems in controlling their blood glucose levels, weight, and blood pressure.”
Diabetic neuropathy: Segmentation analysis
This pipeline analysis report segments the diabetic neuropathy market based on therapies employed (monotherapy and combination therapy), RoA (oral, topical, intramuscular, and intravenous), therapeutic modality (small molecule, peptide, biological, monoclonal antibody, cell therapy, antibody, rhIL-6, and gene therapy), targets (calcium channel, cannabinoid receptor type 2, TRPV1, and others), MoA (calcium channel blocker, cannabinoid receptor type 2 agonist, and others), geographical segmentation (US, Hungary, Japan, South Korea, Poland, Taiwan, Austria, Germany and others) and recruitment status (active, not recruiting, completed, planned, and recruiting). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.
Based on therapeutic modality, more than 46% of the molecules that are being investigated for the treatment of diabetic neuropathy are small molecule.
Looking for more information on this market? Request a free sample report
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Scope of the Report
Drug Development Landscape
- Drugs under development
- Indications coverage
Drug Development Strategies
- Therapies employed
- Therapeutic modality
- Geographical coverage
- Recruitment status
- Type of players
- Company overview
Discontinued or Dormant Molecules
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at firstname.lastname@example.org.